Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143845 · ClinicalTrials.gov registry record · Phase 2
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
A Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT00143845 is a Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 54 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00143845, a Phase 2 study of Multiple Myeloma and Lymphocytic Leukemia, Chronic, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
Conditions Studied
Interventions
- PROCEDURE Reduced intensity conditioning
- PROCEDURE Rapid immunosuppressive taper
- PROCEDURE Prophylactic donor leukocyte infusions
Study Locations (1)
Michigan
- The University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2003-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143845
The ClinicalTrials.gov registry entry for NCT00143845 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Reduced intensity conditioning is the first listed.
NCT00143845 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00143845 about?
NCT00143845 is a clinical study titled "Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant". The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
What is the current status of trial NCT00143845?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2003-04. Estimated completion is 2013-02.
What conditions does trial NCT00143845 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade.
What interventions are being tested in trial NCT00143845?
The interventions under investigation include: Reduced intensity conditioning (PROCEDURE), Rapid immunosuppressive taper (PROCEDURE), Prophylactic donor leukocyte infusions (PROCEDURE).
Who is sponsoring clinical trial NCT00143845?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143845 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.